Inductive Bio, a New York-based startup, has announced a $25 million Series A funding round aimed at transforming small molecule drug discovery through advanced artificial intelligence. The round was led by Obvious Ventures, with participation from prominent investors including Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective. Notable angel investors such as Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit also contributed to the funding.
Addressing the Bottlenecks in Drug Discovery
The pharmaceutical industry faces mounting challenges, including escalating costs, prolonged development timelines, and increasing competition. A critical hurdle in preclinical drug development is optimising a compound's ADMET properties: absorpt
Inductive Bio Nets $25 Million to Predict Better Drugs with AI
- By Upasana Banerjee
- Published on
The newly secured funding will enable Inductive Bio to expand its AI model research and development, grow its data consortium, and deploy its technology industry-wide
